Systemic Lupus Erythematosus

Feb 02, 2021

Horizon Therapeutics Bolsters its Rare Disease Portfolio in a $3B Viela Bio Buyout Horizon Therapeutics has announced to acquire Viela Bio for about $3.1 billion to augment its portfolio and pipeline of treatments for rare diseases. The shares of Viela Bio skyrocketed more than 52% in premarket trading after the...

Jan 26, 2021

Hot on the heels, Aurinia launches its drug in the Lupus market after GSK Aurinia Pharmaceuticals has recently got the USFDA approval for its Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active Lupus nephritis (LN). Lupkynis is the first o...

Apr 13, 2020

Amid the political debate, the US NIH has last week begun the clinical trials of the malarial drug hydroxychloroquine to test its efficacy and safety in patients with COVID-19. What is hydroxychloroquine?  Hydroxychloroquine (HCQ) (aka hydroxychloroquine sulfate), is a drug available in the market to tre...

Dec 18, 2017

Systemic Lupus Erythematosus (SLE) is a chronic, multisystem, inflammatory autoimmune disease which leads to weakening of the immune system. It results in systemic inflammation which affects multiple organs such as kidneys, the tissue lining the lungs (pleura), heart (pericardium), and brain. Acute Cutaneous Lupus, ...

Dec 28, 2016

Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease. The disease has a highly variable course and prognosis. The term lupus has been used to identify a number of chronic, autoimmune diseases that can damage any part of the body (such as skin, joints, and/or organs inside the body). Common symptoms in...